Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Trial symbols : Enlv save search
Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis
Published: 2024-04-16 (Crawled : 12:00) - globenewswire.com
ENLV | $1.48 2.07% 1.36% 5.6K
|
Health Technology
|
| O: -12.58%
H: 10.61%
C: 9.85%
osteoarthritis authorization for trial
Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis
Published: 2024-04-11 (Crawled : 19:00) - globenewswire.com
ENLV | $1.48 2.07% 1.36% 5.6K
|
Health Technology
|
| O: 3.28%
H: 2.12%
C: -16.4%
topline trial results
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
Published: 2024-04-11 (Crawled : 12:00) - globenewswire.com
ENLV | $1.48 2.07% 1.36% 5.6K
|
Health Technology
|
| O: -44.19%
H: 1.36%
C: -17.19%
topline trial results
Enlivex Completes Enrollment Of All 120 Patients In Phase 2 Trial Of Allocetra In Patients With Sepsis, Third-Leading Cause Of Mortality In US Hospitals
Published: 2024-02-21 (Crawled : 15:00) - biospace.com/
ENLV | $1.48 2.07% 1.36% 5.6K
|
Health Technology
|
| O: -0.61%
H: 0.62%
C: -0.92%
trial
Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis
Published: 2024-01-17 (Crawled : 13:00) - globenewswire.com
ENLV | $1.48 2.07% 1.36% 5.6K
|
Health Technology
|
| O: 1.75%
H: 0.69%
C: -1.37%
osteoarthritis authorization trial
Enlivex Announces Completion of Enrollment of Its Phase II Trial Evaluating Allocetra In Patients With Sepsis
Published: 2023-12-20 (Crawled : 13:00) - globenewswire.com
ENLV | $1.48 2.07% 1.36% 5.6K
|
Health Technology
|
| O: 2.52%
H: 41.1%
C: 19.94%
trial
Enlivex Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra™ In Patients With Sepsis
Published: 2023-07-31 (Crawled : 12:00) - globenewswire.com
ENLV | $1.48 2.07% 1.36% 5.6K
|
Health Technology
|
| O: -2.41%
H: 8.64%
C: 5.35%
trial
Enlivex Receives Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra combined with chemotherapy in patients with peritoneal metastases arising from solid cancers
Published: 2023-03-20 (Crawled : 12:20) - globenewswire.com
ENLV | $1.48 2.07% 1.36% 5.6K
|
Health Technology
|
| O: -1.69%
H: 7.14%
C: 4.57%
positive clearance trial
Enlivex Receives Clearance From Spanish Agency of Medicines and Medical Devices For Treatment of Patients with Advanced Solid Malignancies in the Ongoing Allocetra Phase I/II Clinical Trial
Published: 2023-02-23 (Crawled : 15:00) - globenewswire.com
ENLV | $1.48 2.07% 1.36% 5.6K
|
Health Technology
|
| O: 1.87%
H: 0.0%
C: -0.76%
treatment clearance ongoing medical trial
Enlivex Announces Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra in Patients with Advanced Solid Tumors
Published: 2023-01-25 (Crawled : 14:00) - globenewswire.com
ENLV | $1.48 2.07% 1.36% 5.6K
|
Health Technology
|
| O: 1.63%
H: 2.97%
C: 1.6%
clearance trial tumors positive
Enlivex Receives Authorizations from French and Belgian Regulatory Agencies To Expand Its Phase II Sepsis Clinical Trial Into France and Belgium
Published: 2023-01-04 (Crawled : 17:00) - biospace.com/
ENLV | $1.48 2.07% 1.36% 5.6K
|
Health Technology
|
| O: 1.69%
H: 0.02%
C: -1.9%
trial
Enlivex Announces Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors
Published: 2022-11-15 (Crawled : 13:00) - globenewswire.com
ENLV | $1.48 2.07% 1.36% 5.6K
|
Health Technology
|
| O: 1.55%
H: 6.96%
C: 4.57%
trial tumors
Enlivex Announces Regulatory Clearance in Multiple Countries for Integration of Frozen Allocetra Formulation and Expansion of Patient Population in its Sepsis Phase II Clinical Trial
Published: 2022-08-24 (Crawled : 12:20) - globenewswire.com
ENLV | $1.48 2.07% 1.36% 5.6K
|
Health Technology
|
| O: 0.0%
H: 16.48%
C: 11.17%
clearance expansion integration trial
Enlivex Receives Israeli Ministry of Health Approval for the Initiation of a Phase I/II Trial Evaluating Allocetra™ Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors
Published: 2022-08-17 (Crawled : 13:00) - biospace.com/
ENLV | $1.48 2.07% 1.36% 5.6K
|
Health Technology
|
| O: 1.94%
H: 0.29%
C: -1.33%
health trial approval
Sheba Medical Center and Enlivex Announce Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Combined with Chemotherapy in Patients with Peritoneal Metastases Arising from Solid Cancers
Published: 2022-07-06 (Crawled : 13:00) - globenewswire.com
ENLV | $1.48 2.07% 1.36% 5.6K
|
Health Technology
|
| O: -0.22%
H: 8.35%
C: 2.2%
trial
Enlivex Receives Israeli Ministry of Health Authorization for the Initiation of a Phase I/II Trial Evaluating Allocetra Combined with Chemotherapy in Patients with Peritoneal Metastases Arising from Solid Cancers
Published: 2022-06-06 (Crawled : 19:00) - biospace.com/
ENLV | $1.48 2.07% 1.36% 5.6K
|
Health Technology
|
| O: -0.19%
H: 1.75%
C: -0.39%
health trial authorization
Enlivex Receives Regulatory Authorization to Expand its Phase IIb Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients into Greece
Published: 2021-12-13 (Crawled : 16:00) - biospace.com/
ENLV | $1.48 2.07% 1.36% 5.6K
|
Health Technology
|
| O: -2.41%
H: 0.0%
C: 0.0%
covid-19 trial covid authorization
Enlivex Receives Regulatory Authorization to Expand its Phase II Sepsis Trial into Greece
Published: 2021-12-07 (Crawled : 15:00) - biospace.com/
ENLV | $1.48 2.07% 1.36% 5.6K
|
Health Technology
|
| O: -4.49%
H: 9.39%
C: 8.18%
trial authorization
Spanish Regulator Grants Enlivex Authorization to Expand its Phase IIb Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients into Spain
Published: 2021-11-10 (Crawled : 20:00) - biospace.com/
ENLV | $1.48 2.07% 1.36% 5.6K
|
Health Technology
|
| O: 0.83%
H: 3.75%
C: -1.41%
covid trial
Enlivex Doses First Patient in Placebo-Controlled Phase IIb Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients with ARDS
Published: 2021-09-22 (Crawled : 11:00) - globenewswire.com
ENLV | $1.48 2.07% 1.36% 5.6K
|
Health Technology
|
| O: 0.44%
H: 0.87%
C: -0.96%
covid trial
Gainers vs Losers
| 47% | 53% |
Top 10 Gainers
AGBA | $1.44 260.0% 40M
|
Finance
BPTH | $6.25 92.9% 20M
|
Health Technology
BNTC | $5.91 23.13% 1.3M
|
Health Technology
XPON | $2.33 20.73% 410K
|
BRSH | $0.0515 15.99% 12M
|
n/a
VTNR S | $1.12 14.38% 470K
|
Industrial Services
DXYZ 4 | $33.49 13.41% 210K
|
n/a
BMI 4 | $169.84 11.01% 68K
|
Producer Manufacturing
CTM | $0.244 10.86% 40K
|
n/a
DXF | $0.2999 10.75% 150K
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.